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Abstract S-Nitroso-cysteine (SNC), a putative endothelium-
derived relaxing factor, potently inhibited collagen- and arachi-
donic acid-induced platelet aggregation (IC50 = 100 nM) and
thromboxane A2 (TxA2) synthesis of human blood platelets.
ODQ, a selective inhibitor of the soluble guanylyl cyclase,
inhibited SNC-induced formation of cGMP but did not reverse
inhibition by SNC of collagen- and arachidonic acid-induced
platelet aggregation. Combination of ODQ with SQ-29548, a
specific platelet TxA2 receptor antagonist, did not modify the
antiaggregatory action of SNC. Our study shows that SNC
inhibits platelet aggregation by cGMP-independent mechanisms
that may involve inhibition of TxA2 synthesis in human platelets.
z 1999 Federation of European Biochemical Societies.
Key words: Aggregation; S-Nitroso-L-cysteine;
1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one; SQ-29548;
cGMP; S-Nitrosylation
1. Introduction
The mechanism by which endothelium-derived relaxing fac-
tor (EDRF), nitric oxide (NO), S-nitroso compounds, sodium
nitroprusside (SNP) and other NO-containing compounds act
as inhibitors of platelet aggregation and vasodilators is
thought to be by activation of the soluble guanylyl cyclase
(sGC) following binding of NO to the heme moiety of this
enzyme and subsequent release of cGMP in platelets and in
vascular tissue [1^5]. Recently, a potent and selective inhibitor
of the NO-sensitive sGC was discovered [6]. This compound,
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), has been
reported to inhibit sGC but not to a¡ect the activity of the
particulate guanylyl cyclase, adenylyl cyclase and NO syn-
thase in endothelial cells and platelets [6^8]. By means of
ODQ it has recently been demonstrated that the NO-contain-
ing compounds SNP, 3-morpholinosydnonymine, S-nitroso-
glutathione, S-nitroso-DL-penicillamine and S-nitroso-N-ace-
tyl-DL-penicillamine exert their platelet inhibitory and vaso-
dilatory actions via stimulation of the sGC [6^8].
NO and S-nitroso-cysteine (SNC) are the most favored
chemical structures for L-arginine-derived EDRF [9^17].
EDRF has been reported to inhibit platelet aggregation [18^
23]. Both vasodilatation and inhibition of platelet aggregation
by EDRF have been shown to be associated with the activa-
tion of the sGC [22,23]. At present only a few reports exist on
the e¡ects of SNC on platelets. It has been shown that SNC-
induced inhibition of human platelet secretion correlated with
increases in platelet cGMP levels in vitro [24]. In vivo, SNC
has been shown to be a potent vasodilator causing a reduction
in blood pressure [25,26]. In humans, S-nitroso-glutathione
has been shown to be more e¡ective as an inhibitor of platelet
activation than as a vasodilator [27]. Comparable data on
SNC are currently not available. It has been suggested
[8,28^34] that the platelet-inhibitory action of NO and NO-
containing compounds may include cGMP-independent
mechanisms in addition to the cGMP-dependent mechanism.
In the present work, we investigated the e¡ect of SNC on
aggregation and cGMP formation in human platelets. Utiliz-
ing ODQ and the selective thromboxane A2 (TxA2) receptor
antagonist SQ-29548 [35^37] we demonstrate that SNC inhib-
its platelet aggregation via cGMP-independent mechanisms.
2. Materials and methods
2.1. Materials
Sodium [15N]nitrite (98%+ at 15N) was purchased from Cambridge
Isotope Laboratories (Andover, MA, USA). L- and D-cysteine were
obtained from Aldrich (Steinheim, Germany). SNP and rabbit hemo-
globin (type VI) were bought from Sigma (Deisenhofen, Germany).
ODQ was purchased from ALEXIS Corporation (San Diego, CA,
USA). SQ-29548 was bought from Biomol (Hamburg, Germany).
Collagen was obtained from Hormonchemie (Munich, Germany).
All other chemicals were bought from Merck (Darmstadt, Germany).
SNC and 15N-labeled SNC were synthesized from L- or D-cysteine and
[15N]nitrite as described [38]. The structure of SNC and 15N-labeled
SNC was elucidated by £ow injection analysis electrospray ionization
mass spectrometry as described previously [39]. Intense mass frag-
ments were obtained at m/z 151 and m/z 152 corresponding to the
protonated molecular cations of 14N-labeled and 15N-labeled SNC.
Dilutions of stock solutions in isotonic saline were prepared immedi-
ately prior to the start of the experiments and stored on ice until use.
2.2. Preparation of platelet suspensions
Human blood (10 ml, EDTA as the anticoagulating agent) was
drawn from antecubital veins of healthy volunteers who had not re-
ceived aspirin or other non-steroidal antiphlogistic drugs for at least
10 days. Platelet-rich plasma (PRP) was prepared by centrifugation of
blood (200Ug, 15 min). Platelet-poor plasma (PPP) was prepared
from the remaining volume of blood by centrifugation (400Ug, 15
min). Suspensions of washed platelets (WP) were prepared as de-
scribed [20]. The pellet obtained was washed once with Tris-bu¡ered
saline and the platelets were resuspended in Ca2-containing (0.7 mM)
phosphate-bu¡ered saline (PBS), pH 7.3. The platelet count was ad-
justed to approx. 4U108 cells/ml. The platelets were stored at room
temperature under gentle shaking and used within 3 h.
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2.3. Measurement of platelet aggregation and platelet-derived
cGMP and TxB2
Platelet aggregation measurements were performed in duplicate
with 250-Wl aliquots of WP suspensions (both approx. 108 cells) which
were kept in suspension in the aggregation cuvettes by constant stir-
ring at 37‡C. Platelet aggregation was induced by collagen (1.0 Wg/ml)
or arachidonic acid (1 mM). These agonists were added to the cuv-
ettes 3 min after addition of SNC or SNP. In experiments with ODQ
and SQ-29548, stock solutions were freshly prepared in dimethylsulf-
oxide (DMSO) and further diluted with isotonic saline solutions. 10-Wl
aliquots of the ¢nal solutions were added to the WP suspensions. The
¢nal concentration of DMSO was less than 1 vol%. In the concen-
tration range tested DMSO did not in£uence platelet aggregation.
When ODQ and SQ-29548 were used, WP were preincubated with
either or both for 5 min. Aliquots of SNC, SNP or isotonic NaCl
(serving as a control) solutions were added to the WP suspensions.
Platelet aggregation was monitored for 5 min by the increase in light
transmission according to the method of Born and Cross [40] with an
Apact dual-channel aggregometer (LAbor, Hamburg, Germany). For
measurement of intraplatelet cGMP and TxA2, platelet aggregation
was stopped by the addition of 0.75-ml aliquots of 320‡C cool etha-
nol to each cuvette and suspensions were stored at 380‡C until anal-
ysis. Immediately prior to measurement of cGMP in duplicate by
radioimmunoassay using a [125I]iodotyrosine cGMP derivative as trac-
er (DuPont de Nemours, Dreieich, Germany) as described [41], sam-
ples were thawed and centrifuged at 4‡C (1800Ug, 10 min). Platelet-
derived TxA2 was quantitated as its stable analog TxB2 by gas chro-
matography-tandem mass spectrometry as described elsewhere [42].
2.4. Measurement of NO and intraplatelet [15N]nitrite
NO was measured by an NO electrode equipped with ISO-NOP200,
a 200 Wm diameter shielded micro-sensor (World Precision Instru-
ments, Sarasota, FL). For measurement of intraplatelet [15N]nitrite,
S-[15N]nitroso compounds were incubated (0^200 WM) in 500-Wl ali-
quots of PRP (about 108 platelets) or PPP (used as a control) in
siliconized 1.3-ml conical glass vials for 1 min at room temperature.
After incubation the samples were treated with 500-Wl aliquots of PBS
and centrifuged (200Ug, 5 min). Supernatants were decanted, pellets
were resuspended in 1-ml aliquots of PBS and centrifuged again
(200Ug, 5 min). This procedure was repeated three times. Pellets
from the last centrifugation were resuspended in 100-Wl aliquots of
distilled water. These samples were treated with acetone (400 Wl) and
mixed by vortexing for 1 min in order to disrupt the platelets. After
centrifugation (1800Ug, 5 min) the supernatants were taken up and
treated for quantitation of nitrite by GC-MS [38]. The ratio m/z 47
([15N]nitrite) to m/z 46 (nitrite) was used as a measure of [15N]nitrite
accumulation in platelets.
2.5. Statistical analysis
Values are reported as mean þ S.E.M from experiments on inhibi-
tion of platelet aggregation, cGMP and TxA2 formation and as
mean þ S.D. for results from experiments on accumulation of
[15N]nitrite in the platelets and NO release. The signi¢cance of di¡er-
ences was determined with the paired t-test. P6 0.05 was considered
signi¢cant.
3. Results
Fig. 1 shows that SNC (1.0 WM) almost completely inhib-
ited collagen-induced platelet aggregation (extent of inhibi-
tion, 98 þ 0.2%) whereas ODQ did not a¡ect the inhibitory
action of SNC at all (extent of inhibition, 98 þ 0.2%). In the
absence of ODQ, inhibition of platelet aggregation by SNC
was accompanied by a signi¢cant increase in the cGMP levels
(23.1 þ 5.9 pmol/109 platelets). Even though ODQ had no ef-
fect on the inhibition of aggregation by SNC, ODQ signi¢-
cantly (P6 0.05) inhibited SNC-induced formation of cGMP
(3.8 þ 1.0 pmol/109 platelets). On the other hand, ODQ re-
versed the action of SNP (1.0 WM) partially with respect to
the extent of inhibition (92 þ 0.4 vs. 38.6 þ 9.6%, P6 0.05) and
completely with respect to the cGMP levels (39.4 þ 9.8 vs.
1.76 þ 0.4 pmol/109 platelets, P6 0.05). On a molar basis,
SNP was less e¡ective in inhibiting platelet aggregation than
SNC, but caused a higher formation rate of cGMP, which was
decreased almost to basal levels by ODQ. Fig. 1 shows that
ODQ did not in£uence the extent of collagen-induced platelet
aggregation at all (0.50 þ 0.01% vs. 0.50 þ 0.05%) nor cGMP
levels (1.2 þ 0.2 pmol/109 platelets vs. 1.1 þ 0.2 pmol/109 pla-
telets) suggesting that platelet function is not a¡ected by
ODQ. These results suggest that SNC inhibits platelet aggre-
gation by cGMP-independent mechanisms, and that SNP in-
hibits platelet aggregation both by cGMP-dependent and
cGMP-independent mechanisms.
Fig. 2 shows the dose-response relationship of SNC on
platelet aggregation and cGMP formation. SNC emerges as
a very potent inhibitor (IC50 approx. 100 nM) of collagen-
induced aggregation in human WP. Fig. 2 also shows that
ODQ e¡ectively inhibited SNC-induced formation of cGMP
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Fig. 1. E¡ect of ODQ (10 WM) on the extent of inhibition of colla-
gen-induced (1 Wg/ml) aggregation of washed platelets and intrapla-
telet cGMP formation by 0.9% NaCl, SNC and SNP each at 1 WM.
Data are presented as mean þ S.E.M., n = 4^7.
Fig. 2. E¡ect of various concentrations of SNC on the extent of in-
hibition of collagen-induced (1 Wg/ml) aggregation of washed plate-
lets and intraplatelet cGPM formation in the presence (10 WM) and
in the absence of ODQ. Data are presented as mean þ S.E.M, n = 3.
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but did not signi¢cantly a¡ect the inhibition of aggregation by
SNC. No signi¢cant di¡erences were found between L-SNC
and D-SNC (each at 1 WM) with respect to both the extent of
platelet inhibition and cGMP levels in the presence and in the
absence of ODQ (data not shown).
Fig. 3 shows that L-SNC and D-SNC are equally e¡ective
and much more potent NO donors than S-nitroso-glutathione
(GSNO). SNP and nitrite did not release any NO under the
experimental conditions used.
Intraplatelet formation of [15N]nitrite ^ expressed as the
ratio of m/z 47 to m/z 46 ^ was observed when platelets
from PRP were incubated with 15N-labeled L-SNC or 15N-
labeled D-SNC (Fig. 4) but not with 15N-labeled GSNO or
[15N]nitrite (not shown). No accumulation of [15N]nitrite was
found when platelets from PPP used as control were incu-
bated with 15N-labeled L-SNC. Intraplatelet accumulation of
[15N]nitrite was found to depend on the concentration of 15N-
labeled L-SNC (Fig. 5) and to be inhibited by a molar excess
of hemoglobin over 15N-labeled L-SNC and 15N-labeled D-
SNC (data not shown).
Arachidonic acid-induced platelet aggregation was com-
pletely inhibited by acetylsalicylic acid (ASA) and SNC (Fig.
6A). While ASA completely inhibited TxA2 formation, SNC
caused only partial inhibition of TxA2 formation in platelets.
ODQ did not reverse the e¡ects of SNC on either platelet
aggregation or TxA2 formation (Fig. 6A). Fig. 6B shows
that the combination of ODQ with SQ-29548 weakly inhibited
collagen-induced platelet aggregation. In the presence of ODQ
and SQ-29548, SNC completely inhibited collagen-induced
aggregation (Fig. 6B). SQ-29548 (1 WM) completely inhibited
arachidonic acid-induced platelet aggregation (not shown).
4. Discussion
The present study shows for the ¢rst time that SNC, a
putative EDRF, inhibits potently collagen- and arachidonic
acid-induced aggregation of platelets by cGMP-independent
mechanisms. This work also shows for the ¢rst time that
SNC inhibits TxA2 synthesis in human platelets. Our results
suggest that inhibition of TxA2 synthesis and/or antagoniza-
tion of the TxA2 receptor of the platelets are novel cGMP-
independent mechanisms by which SNC inhibits platelet ag-
gregation. The mechanism involving inhibition of TxA2 for-
mation in the platelets is supported by the recent ¢nding of
our group that intravenous infusion of L-arginine in healthy
volunteers resulted in NO-associated inhibition of platelet
TxA2 formation ex vivo [43]. This mechanism is also sup-
ported by the observation that SNC and other S-nitroso com-
pounds including S-nitroso-glutathione inhibit TxA2 synthesis
by isolated cyclooxygenase (unpublished observations). The
¢nding that SNC inhibits platelet aggregation despite com-
plete inhibition of the sGC and complete antagonization of
the TxA2 receptor of the platelets suggests that additional
cGMP-independent mechanisms for SNC may exist. These
mechanisms could include inhibition of the low KM cAMP
phosphodiesterase, of glyceraldehyde 3-phosphate dehydro-
genase, ADP ribosylation, and increases in intracellular
Ca2 concentrations independent of sGC [28^34].
Incubation of L- and D-SNC with human platelets did not
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Fig. 5. Two sets of six 500-Wl aliquots of PRP were incubated sepa-
rately for 1 min at room temperature with the indicated concentra-
tions of 15N-labeled L-SNC and 15N-labeled nitrite (at 200 WM)
served as the control.
Fig. 4. Two sets of six 500-Wl aliquots of PRP were incubated sepa-
rately for 1 min at room temperature with 200 WM of 15N-labeled
L-SNC or 15N-labeled D-SNC. Six 500-Wl aliquots of PPP were simi-
larly incubated with 15N-labeled L-SNC and served as control.
Fig. 3. L-SNC, D-SNC, GSNO, SNP and nitrite were separately in-
cubated in 50 mM potassium phosphate bu¡er at pH 7.4 at the in-
dicated concentrations. Each experiment was performed in triplicate.
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result in signi¢cantly di¡erent inhibition of aggregation and
intraplatelet levels of nitrite. A possible explanation for the
apparent non-stereoselective antiaggregatory action of L- and
D-SNC may be that activation of sGC, inhibition of TxA2
synthesis in the platelets and possibly other cGMP-independ-
ent mechanisms were not caused by L- or D-SNC themselves
but by NO which was released outside the platelets by these
compounds that are equally potent NO donors. However,
rapid free di¡usion of SNC-derived NO and slower trans-
membranous transport of SNC into the platelets could take
place simultaneously so that the di¡erences in the e¡ects
caused by transmembranously transported L- or D-SNC could
be abolished. Therefore, the cGMP-independent antiaggrega-
tory actions of SNC could indeed be initiated by a speci¢c
transport system for SNC in human platelets. In contrast to
SNC, SNP is a poor spontaneous NO donor. It seems likely
that SNP activates the sGC by itself by directly binding to this
enzyme rather by NO released from SNP. In the cGMP-in-
dependent mechanism, intraplatelet SNP could act by the
mechanisms mentioned above for NO [28^34] but at a much
weaker potency than SNC.
Our study shows that SNC potently stimulates the sGC.
Although ODQ did not reverse the antiaggregatory action
of SNC our study does not exclude that SNC inhibits platelet
aggregation by a cGMP-dependent mechanism too, analogous
to SNP and to other S-nitroso compounds such as S-nitroso-
penicillamine and S-nitroso-N-acetyl-penicillamine [8]. Obvi-
ously, the cGMP-dependent mechanism of SNC is substan-
tially less potent than the cGMP-independent mechanisms.
Further, it is possible that the cGMP-independent mecha-
nisms of SNC di¡er from those of other S-nitroso com-
pounds.
An alternative cGMP-independent mechanism of the inhi-
bition of platelet aggregation by SNC could involve S-nitro-
sylation of platelet membrane constituents such as the TxA2
receptor. This mechanism is supported by the high nitrosylat-
ing potency of SNC against proteins and enzymes [44,45], the
existence of membrane-bound S-nitroso compound receptors
within the cardiovascular system [26], and the ¢nding that S-
nitroso compounds are targeted to red blood cells [46].
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